NS5B polymerase inhibitors in phase II clinical trials for HCV infection. (4th March 2018)

• Record Type: Journal Article
• Authors: Borgia, Guglielmo; Maraolo, Alberto Enrico; Nappa, Salvatore; Gentile, Ivan; Buonomo, Antonio Riccardo
• Is Part Of: Expert opinion on investigational drugs. Volume 27:Number 3(2018)
• Page Start: 243
• Page End: 250
• Publication Date: 2018-03-04
• Subjects: Hepatitis C -- HCV -- NS5B -- direct-acting antiviral agents -- Uprifosbuvir -- TMC-647 -- 055 -- AL-335 -- Radalbuvir; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2018.1420780
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Hepatitis C virus (HCV) infection might be the first chronic viral disease to be eradicated without the introduction of a prophylactic vaccine. This is essentially due to therapeutic revolution encapsulated by the advent of direct-acting antivirals (DAA) agents, whose efficacy, safety and tolerability (all oral regimens) have made the previous standard of care (interferon plus ribavirin) a vestige of the past. The new regimens achieve very high response rates and have an excellent tolerability profile. Notwithstanding, the first wave of DAAs has brought over problems regarding costs and failures which warrant research and development of further antiviral molecules. Areas covered : This review outlines the main clinical data concerning novel NS5B polymerase inhibitors currently in pipeline, focusing on the ones that have completed a phase 2 trial. Expert opinion : NS5B is one the main viral target for anti-HCV therapy. The large majority of the approved regimens so far include a NS5B inhibitor. Although not frequently, failure related to mutations can occur. The potential place in therapy in the mid-term of new NS5B inhibitors may be, in the first instance, the role of backbone in salvage combinations with DAAs of other classes.